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Introduction
Methods are currently being explored
which would permit the application of cyto-
genetic procedures such as metaphase and
anaphase analyses to in vivo mammalian
systems in order that due consideration
may be given to metabolic activation or de-
toxification reactions which might affect
the mutagenic or clastogenic (chromosome
breaking) potential of environmental
agents under study. It has been recom-
mended (1) that such in vivo cytogenetic
methods be employed in mutagenicity test-
ing programs which are being designed to
evaluate mutagenic potentials and risk-
benefit ratios of a wide variety of drugs and
other chemical agents when human expo-
sure is involved.
Metaphase chromosome analysis has been
adapted readily to in vivo testing of chemi-
cal mutagens (2-5). More recently, Palmer,
Kelly-Garvert, and Legator (6) have de-
scribed a potentially useful method for in
vivo collection of anaphase figures from rat
bone marrow cells which involves the appli-
cation of a mitotic arresting agent (colce-
mide, CIBA, New Jersey) in vivo, followed
by a short-term in vitro incubation (1-11,i2
hr) in the absence of colcemide to reconsti-
tute spindle fibers and initiate anaphase
movement. Preliminary studies with the in
viv.o anaphase method in our laboratory
have revealed a number of technical limita-
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tions which have restricted its value for
rapid screening of potential clastogenic
agents; the most troublesome of these being
the extremely small size of the anaphase
figures obtained, necessitating time-
consuming scanning of slides using oil im-
mersion optics, and the relatively high base-
line aberration rate of approximately 10%o
in preparations from untreated control ani-
mals, leading to serious questions regarding
the sensitivity of the procedure.
The purpose of this paper is to outline
work being done on an alternative method
for scoring in 'vivo clastogenic effects of po-
tential mutagens which may provide a
method for the rapid screening of large
numbers of chemical compounds: the bone
marrow "rmicronucleus test" as modified by
Schmid and his co-workers at the Univer-
sity of Zurich. (7).
Rationale
The micronucleus test (7) affords a pro-
cedure for the detection of aberrations in-
volving anaphase chromosome behavior uti-
lizing a particularly useful cell type, the
bone marrow erythroblast. The test is based
on the formation of "micronuclei" from
particles of chromatin material which, due
to chromosome breakage or spindle dysfunc-
tion, do not migrate to the poles during
anaphase and are not incorporated into the
telophase nuclei of the dividing cell. Such
chromatin fragments, or even whole chro-
mosomes in the case of chromosome lag, re-
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satellite nuclei in the cytoplasm of the
daughter cells. In animals treated with
known clastogenic agents such as 2,3,5-tris-
(ethylenimino)-1,4-benzoquinone (Treni-
mon, Bayer) or mitomycin-C, micronuclei
are found in the cytoplasm of the various
bone marrow cells; erythroblasts, myelo-
blasts, myelocytes, erythrocytes, etc.
Schmid and his colleagues (7,8) have re-
ported that the majority of the micronuclei
detected in such preparations are found in
the erythrocytes. Moreover, when treat-
ment time With the clastogenic agent is be-
tween 24 and 30 hr, the majority of these
micronuclei are found in the newly formed
polychromatic erythrocytes (8).
For the purpose of detecting genetic dam-
age in the form of chromosome disrupting
c.apacity the polychromatic erythrocytes of
the bone marrow have some very useful
characteristics. The expulsion of the mam-
malian erythrocyte nucleus follows the final
mitotic division by several hours, but the re-
sulting enucleated erythrocyte retains its
cytoplasmic basophilia for approximately
24 hr after nuclear expulsion. In addition,
it appears that micronuclei in the cyto-
plasm of these cells are not expelled with
the nucleus. It is therefore possible after 24
hr of treatment to examine the bone mar-
row of a test animal and discriminate be-
tween erythrocytes formed during the
treatment time and tihose formed prior to
exposure. In this situation each animal may
be considered to serve as its own control in-
asmuch as the frequency of micronuclei in
the polychromatic erythrocytes, formed
during treatment, may be compared with
the frequency of micronuclei in the normo-
chromatic erythrocytes, formed prior to
treatment. Any clastogenic response dur-
ing the 24-hr time interval would result in
an increase in the frequency of micronuclei
only in the polychromatic erythrocyte popu-
lation. Work done with two strong alky-
lating mutagens, Trenimon and mitocycin-
C, has produced results which are in agree-
ment with these expectations and which
will be discussed at the end of this paper.
Preparation and Evaluation of Bone
Marrow Smears
One of the most attractive aspects of the
micronucleus test is the relative speed with
which it can be done. The procedure is con-
siderably less time consuming than either
in vivo anaphase or metaphase analysis,
both in terms of slide preparation and eval-
uation.
At the appropriate time after treatment,
bone marrow samples are aspirated into
calf serum, centrifuged, and smears made
from the resuspended pellet of cells. When
experimental animals are used they may be
sacrificed and the shaft of the femur flushed
with serum. Smears are air-dried and
stained with Wright's stain or May-
Grunwald-Giemsa (8).
Evaluation of the bone marrow prepara-
tions involves examination of from 2000 to
5Q00 erythrocytes per specimen, all other
cell types being ignored. The total numbers
of polychromatic erythrocytes with and
without micronuclei as well as the total
number of normochromatic erythrocytes
with and without micronuclei are recorded.
Interpretation is relatively straightfor-
ward, and if only the erythrocytes are
examined, the evaluation requires a mini-
mum of training and may be performed
quite reliably by relatively unskilled micro-
scopists. Several potential difficulties should
however be mentioned. The first involves the
discrimination of the polychromatic ery-
throcytes themselves. Particularly in nega-
tive control specimens or the lower treat-
ment dose levels the polychromasy is vari-
able and is manifest as a continuum from
blueish basophilic erythrocytes to mature
pinkish normochromatic erythrocytes, ne-
cessitating a decision on the majority of cells
on the slide. An additional source of poten-
tial difficulty involves the presence, particu-
larly in rat bone marrow smears, of baso-
philic granules from ruptured basophilic
myelocytes which have staining chracteris-
tics and morphology similar to micronuclei.
These granules may be mistaken for micro-
nuclei when they are superimposed over the
erythrocytes in the area of the ruptured
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guish between such granules on the surface
of the erythrocytes and true micronuclei
present within the cytoplasm. Platelets may
also be a source of confusion to the novice,
but their characteristic diffuse pale staining
appearance should make discrimination of
superimposed platelets a matter of little real
difficulty.
Effects of Strong Mutagens
Preliminary work with the micronucleus
test has to date been confined to experi-
ments with a very few potent clastogenic
agents, including Trenimon and mitomycin-
C. Matter and Schmid (8) have demon-
strated a dose-dependent increase in the in-
cidence of micronuclei in the bone marrow
erythrocytes of six species of laboratory
mammals by using Trenimon in doses
ranging from 0.031 to 0.25 mg/kg. In an-
other similar study, Boller and Schmid (7),
utilizing Trenimon in the Chinese hamster,
reported that the dose-dependent increase
in formation of micronuclei is highly corre-
lated with the results of cytogenetic studies
on the incidence of chromosome aberrations
obtained under identical experimental con-
ditions utilizing metaphase analysis. The
levels of the drug found necessary to cause
an increase in detectable aberrations in vivo
using the two tests were very similar.
The results of a pilot study done with
mitocycin-C in our laboratory are found in
Table I and will serve to illustrate some of
the strengths and limitations of the test. In
this experiment female Amsterdam rats
were treated with 3,ug/g body weight of mi-
tomycin-C for 24 and 48 hr prior to sacrifice
(groups 3, 4, 5, 6, Table 1). Two groups of
rats (3 and 5) also received 4MAg/g body
weight of colcemide 4 hr prior to killing in
order that bone marrow metaphase chromo-
some preparations could be analyzed in ad-
dition to micronuclei from the same sets of
animals. One group (1) received only colce-
mide, and another group (2) received no
treatment.
Table 1. Female Amsterdam rats 10-15 weeks of age treated with colcemide and mitomycin-C.
Micro- Micro- Poly-
nuclei nuclei Micro- chromatic
in normo- in poly- nuclei Cells with
Time, chromatic chromatic in total Normo- metaphase
Groupb Animals Treatment hr RBC RBC RBC chromatic aberrations
1 3 Colcemide 4 7/4972 4/1028 11/6000 1028/6000 1/150
(0.14%) (0.39%) (0.18%) (17.1%o) (0.7%)
2 3 2/4132 4/1868 6/6000 1868/6000 -
(0.05%1c) (0.21%) (0.10%) (31.1%)
3 3 Mitomycin-C 24 4/5037 11/963 15/6000 963/6000 67/150
+ colcemide 4 (0.08%/) (1.14%) (0.25%) (16.1%) (44.7%)
4 3 Mitomycin-C 24 3/5017 10/983 13/6000 986/6000
(0.06%) (1.02%) (0.22%l,) (16.6%s)
5 3 Mitomycin-C 48 8/5721 2/279 10/6000 279/6000 4/150
+ colcemide 4 (0.14%) (0.72%) (0.17,%) (4.7%) (2.7%)
6 2 Mitomycin-C 48 19/3825 6/175 25/4000 175/4000
(0.50%) (3.43%) (0.63%) (4.4%,)
a Colcemide: 4,g/g, 1 injection IP; mitomycin-C: 3Ag/g, 1 injection IP.
b Group 1: female rats treated with 4,ug/g body weight of colcemide and sacrificed 4 hr later; group 2: un-
treated negative controls; group 3: animals received 3-ug/g mitomycin-C and were sacrificed 24 hr
after treatment (this group also received 4,ug/g colcemide 4 hr prior to death; group 4: received 3,ug/g
mitomycin-C 24 hr prior to sacrifice; group 5: treated with mitomycin-C 48 hr and colcemide 4 hr prior
to sacrifice; group 6: received only mitomycin-C 48 hr prior to sacrifice.
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pected that the incidence of micronuclei in
normochromatic erythrocytes would remain
constant through the first 24 hr of clastogen
treatment and increase only after erythro-
cytes formed during the treatment interval
become normochromatic (see groups 2, 4
and 6). It would also be expected that the
incidence of micronuclei in the polychroma-
tic erythrocytes would increase signifi-
cantly after 24 hr of treatment (see groups
2 and 4). Both of these expectations are
borne out by these data. Matter and Schmid
(8) have suggested that the latter effect
may be maximized if two treatments, rather
than one, are given 24 hr apart and the ani-
mals sacrificed 6 hr after the last treatment.
Since it would be useful to be able to
compare metaphase aberrations with micro-
nuclei production in the same animals, half
of the control animals and half of the two
mitomycin-treated groups received an injec-
tion of colcemide 4 hr prior to sacrifice. It
seems evident even from these limited data
that the 4-hr colcemide treatment does tend
to influence the frequency of micronuclei
found in the erythrocytes (groups 1, 2, 5,
and 6). Only in the 24-hr mitomycin treat-
ment groups (groups 3 and 4) was such an
effect not detected. Further work will of
course be required to properly evaluate these
initial observations. It should be noted how-
ever, that the colcemide-treated control rats
had proportionately fewer polychromatic
erythrocytes in their marrow than the un-
treated control group, and it is conceivable
that the colcemide exerted this latter effect
by blocking nuclear expulsion through dis-
ruption of microtubule formation. The de-
crease in the ratio of polychromatic to
normochromatic erythrocytes with length
of mitomycin treatment (see groups 2, 4
and 6) is construed as evidence of its toxic
effect on marrow components.
For purposes of rapid screening of poten-
tial clastogenic agents it appears that the
micronucleus test holds considerable prom-
ise. In our hands the time required for count-
ing 2000 erythrocytes averaged about 15
min. This compares with approximately 1
hr for counting and analysis of 50 metaphase
spreads and nearly 2 hr for analysis of 50
rat bone marrow anaphase figures.
It is suggested that a more rigorous eval-
uation of the micronucleus test as an in vivo
method for mutagenicity screening must
await further experimentation utilizing a
variety of both strongly and weakly muta-
genic compounds and sensitivity compari-
sons with more firmly established muta-
genicity testing protocols.
REFERENCES
1. Nichols, W. W., Moorhead, P., and Brewen, G.
Ad hoc committee report on chromosome method-
ologies in mutation testing. Toxicol. Appl.
Pharmacol. 22: 269 (1972).
2. Schleiermacher, E., et al. Mutation durch
chemische Einwirkung bei Sanger und Mench.
Zytogenetische Untersuchungen in vivo und in
vitro. Deut. Med. Wschr. 92: 2343 (1967).
3. Kato, R., Bruze, M., Tegner, Y. Chromosome
breakage induced in vivo by a carcinogenic
hydrocarbon in bone marrow cells of the Chinese
hamster. Hereditas 61: 1 (1969).
4. Legator, M. S., et al. Cytogenetic studies in rats
of cyclohexylamine, a metabolite of cyclamate.
Science 165: 1139 (1969).
5. Schmid, W., et al. Chemical mutagenesis. The
Chinese hamster bone marrow as an in vivo test
system. I. Cytogenetic results on basic aspects of
methodology, obtained with alkylating agents.
Humangenetik 11: 103 (1971).
6. Palmer, K. A., Kelly-Garvert, F., and Legator,
M. S. Method for preparing anaphase figures
from rat bone marrow. Mutation Res. 16: 111
(1972).
7. Boller, K., and Schmid, W. Chemische Mutagenese
beim Sanger. Das Knochenmark des Chinesischen
Hamsters als in vivo Test system. Hamatologische
Befundenach Behandlung mit Trenimon. Human-
genetik 11: 34 (1970).
8. Matter, B., and Schmid, W. Trenimon-induced
chromosomal damage in bone marrow cells of six
mammalian species, evaluated by the micronu-
cleus test. Mutation Res. 12: 417 (1971).
170 Environmental Health Perspectives